Health
Aptamer Group and Mologic enter commercial partnership to develop aptamer-based SARS-CoV-2 rapid antigen test – News-Medical.net
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic.
Aptamer Group, the developer of diagnostic and therapeutic Optimer™ reagents, today announced a commercial partnership with Mologic, a leading developer and manufacturer of lateral flow and rapid diagnostic tests.
The partnership will work towards CE marking of Aptamer Group’s AptaDx SARS-CoV-2 lateral flow rapid antigen test for professional use, to detect the SARS-CoV-2 spike protein antigen in anterior nasal swabs. Initial test analysis with laboratory samples has demonstrated excellent sensitivity…
-
Noosa News21 hours agoRallies under way as nationwide support for Palestine surges
-
Noosa News22 hours agoHusband charged after beloved Brisbane nurse Carra Luke allegedly stabbed to death in Taigum home
-
General21 hours agoTens of thousands protest in nationwide action against war in Gaza
-
General24 hours agoNRL live updates: Newcastle Knights vs Brisbane Broncos, Wests Tigers vs North Queensland Cowboys — blog, scores and stats